Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 79X: Nivolumab Combinations in Advanced NSCLC
NCT04151563Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Primary endpoint: Overall Response Rate at 33 months. Planned start Apr 2021; status: withdrawn.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04151563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04151563.